Important information regarding Medicare GLP-1 Bridge through CMS

The Centers for Medicare & Medicaid Services (CMS) is expanding access to certain GLP-1 medications through the Medicare GLP-1 Bridge short-term demonstration starting July 1, 2026. Medicare GLP-1 Bridge operates outside of Medicare Part D plan coverage and uses a central processor to manage prior authorization, claims processing, and pharmacy payment. This program is for eligible Medicare Part D beneficiaries using GLP-1 medications for the sole purpose of reducing excess body weight and maintaining weight reduction. Beneficiaries must not be eligible to receive GLP-1 medications through their Part D plan and must not have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). Learn more at cms.gov/files/document/glp-1-prescribers-c-1.pdf.